Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial

被引:3
作者
Watson-Jones, Deborah [1 ,2 ]
Changalucha, John [1 ]
Maxwell, Caroline [1 ,2 ]
Whitworth, Hilary [1 ,2 ]
Mutani, Paul [1 ]
Kemp, Troy J. [4 ]
Kamala, Beatrice [1 ]
Indangasi, Jackton [1 ,2 ]
Constantine, George [1 ]
Hashim, Ramadhan [1 ]
Mwanzalima, David [1 ]
Wiggins, Rebecca [5 ,6 ]
Mmbando, Devis [1 ]
Connor, Nicholas [2 ]
Pavon, Miquel A. [7 ,8 ]
Lowe, Brett [2 ]
Kapiga, Saidi [1 ,3 ]
Mayaud, Philippe [2 ]
de Sanjose, Silvia [9 ,10 ]
Dillner, Joakim [11 ]
Hayes, Richard J. [3 ]
Lacey, Charles J. [5 ,6 ]
Pinto, Ligia [4 ]
Baisley, Kathy [3 ]
机构
[1] Natl Inst Med Res, Mwanza Intervent Trials Unit, Mwanza, Tanzania
[2] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England
[3] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England
[4] Leidos Biomed Res, Frederick Natl Lab Canc Res, HPV Serol Lab, Frederick, MD USA
[5] Univ York, York Biomed Res Inst, York, England
[6] Univ York, Hull York Med Sch, York, England
[7] ICO IDIBELL, Canc Epidemiol Res Program, Infect & Canc Lab, Barcelona, Spain
[8] Ctr Biomed Res Epidemiol & Publ Hlth Network CIBER, Madrid, Spain
[9] Inst Global Hlth ISGlobal, Barcelona, Spain
[10] NCI, NIH, Rockville, MD USA
[11] Karolinska Inst, Stockholm, Sweden
基金
英国医学研究理事会; 比尔及梅琳达.盖茨基金会; 英国惠康基金;
关键词
HPV VACCINE; IMMUNOBRIDGING ANALYSIS; SAFETY; RESPONSES; EFFICACY;
D O I
10.1016/S2214-109X(24)00477-7
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background WHO has recommended that one dose of human papillomavirus (HPV) vaccine can be given to individuals aged 9-20 years to prevent HPV infection. Estimating durability of immune responses after a single dose in the target age for vaccination is important. We report immunogenicity results in Tanzanian girls up to 5 years after receiving a dose. Methods In this open-label, randomised controlled trial (the Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls [DoRIS] trial), 930 Tanzanian schoolgirls aged 9-14 years were enrolled and randomly allocated to receive one, two, or three doses of either the two-valent vaccine (Cervarix; GSK, Wavre, Belgium) or nine-valent vaccine (Gardasil-9; Merck Sharp & Dohme, Haarlem, Netherlands). Seropositivity specific to HPV16 or HPV18, antibody geometric mean concentrations (GMCs), and antibody avidity were measured annually up to month 36. Participants in the one-dose and two-dose groups were followed annually in a long-term extension of the DoRIS trial to month 60; the primary outcome was seropositivity specific to HPV16 or HPV18 comparing one dose with two doses. Findings Single-dose seropositivity for HPV16 IgG antibodies at month 60 with either vaccine was more than 99% and non-inferior to two doses. 98% of girls in the one-dose two-valent vaccine group and 93% in the one-dose nine-valent group were seropositive for HPV18 at month 60; however, the non-inferiority criteria for HPV18 seropositivity comparing one dose with two doses were not met. Although HPV16 and HPV18 antibody GMCs after one dose were lower than those observed after two doses, antibody GMCs in the one-dose groups remained stable from month 12 to month 60. There was no evidence of a difference between the one-dose and two-dose groups in HPV16 or HPV18 antibody avidity at month 36 for either vaccine. Interpretation A single dose of HPV vaccine in girls aged 9-14 years continues to provide stable immune responses 5 years after vaccination, although ongoing surveillance for potential waning immunity after a single dose is needed. Participants are being followed up to 9 years after vaccination. Copyright (c) 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
引用
收藏
页码:e319 / e328
页数:10
相关论文
共 32 条
[1]   Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials [J].
Baisley, Kathy ;
Kemp, Troy J. ;
Mugo, Nelly R. ;
Whitworth, Hilary ;
Onono, Maricianah A. ;
Njoroge, Betty ;
Indangasi, Jackton ;
Bukusi, Elizabeth A. ;
Prabhu, Priya R. ;
Mutani, Paul ;
Galloway, Denise A. ;
Mwanzalime, David ;
Kapiga, Saidi ;
Lacey, Charles J. ;
Hayes, Richard J. ;
Changalucha, John ;
Pinto, Ligia A. ;
Barnabas, Ruanne, V ;
Watson-Jones, Deborah .
LANCET GLOBAL HEALTH, 2024, 12 (03) :e491-e499
[2]  
Baisley K, 2022, LANCET GLOB HEALTH, V10, pE1485, DOI 10.1016/S2214-109X(22)00306-0
[3]   A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial [J].
Baisley, Kathy J. ;
Whitworth, Hilary S. ;
Changalucha, John ;
Pinto, Ligia ;
Dillner, Joakim ;
Kapiga, Saidi ;
de Sanjos, Silvia ;
Mayaud, Philippe ;
Hayes, Richard J. ;
Lacey, Charles J. ;
Watson-Jones, Deborah .
CONTEMPORARY CLINICAL TRIALS, 2021, 101
[4]   Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results [J].
Barnabas, Ruanne V. ;
Brown, Elizabeth R. ;
Onono, Maricianah A. ;
Bukusi, Elizabeth A. ;
Njoroge, Betty ;
Winer, Rachel L. ;
Galloway, Denise A. ;
Pinder, Leeya F. ;
Donnell, Deborah ;
Wakhungu, Imelda N. ;
Biwott, Charlene ;
Kimanthi, Syovata ;
Heller, Kate B. ;
Kanjilal, Diane G. ;
Pacella, Daniel ;
Morrison, Susan ;
Rechkina, Elena A. ;
Cherne, Stephen L. ;
Schaafsma, Torin T. ;
McClelland, R. Scott ;
Celum, Connie ;
Baeten, Jared M. ;
Mugo, Nelly R. ;
Dull, Peter ;
Gulati, Reena ;
Vernam, Sara ;
Yousufzay, Abdul Rawuf ;
Gunderson, Krissa ;
Hercinovic, Amra ;
Ondrejcek, Lisa ;
Robertson, Gavin ;
Williams, Angela ;
Brown, Elizabeth ;
Carter, Jody ;
Donnell, Deborah ;
Galloway, Denise ;
Pinder, Leeya ;
Prabhu, Priya R. ;
Smith, Robin ;
Wright, Marci ;
Abiero, Stephen O. ;
Achola, Maqline A. ;
Adipo, Meldah O. ;
Amukonyi, Katherine L. ;
Akinyi, Cynthia ;
Akinyi, Teresia O. ;
Amboka, Penina N. ;
Arum, Karl D. ;
Atogo, Veronica O. ;
Atonga, Pius O. .
NATURE MEDICINE, 2023, 29 (12) :3224-3232
[5]  
Barnabas RV, 2022, NEJM EVID, V1, DOI 10.1056/EVIDoa2100056
[6]   Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study [J].
Basu, Partha ;
Malvi, Sylla G. ;
Joshi, Smita ;
Bhatla, Neerja ;
Muwonge, Richard ;
Lucas, Eric ;
Verma, Yogesh ;
Esmy, Pulikkottil O. ;
Poli, Usha Rani Reddy ;
Shah, Anand ;
Zomawia, Eric ;
Pimple, Sharmila ;
Jayant, Kasturi ;
Hingmire, Sanjay ;
Chiwate, Aruna ;
Divate, Uma ;
Vashist, Shachi ;
Mishra, Gauravi ;
Jadhav, Radhika ;
Siddiqi, Maqsood ;
Sankaran, Subha ;
Prabhu, Priya Ramesh ;
Kannan, Thiraviam Pillai Rameshwari Ammal ;
Varghese, Rintu ;
Shastri, Surendra S. ;
Anantharaman, Devasena ;
Gheit, Tarik ;
Tommasino, Massimo ;
Sauvaget, Catherine ;
Pillai, M. Radhakrishna ;
Sankaranarayanan, Rengaswamy .
LANCET ONCOLOGY, 2021, 22 (11) :1518-1529
[7]   Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males [J].
Bergman, Hanna ;
Buckley, Brian S. ;
Villanueva, Gemma ;
Petkovic, Jennifer ;
Garritty, Chantelle ;
Lutje, Vittoria ;
Riveros-Balta, Alina Ximena ;
Low, Nicola ;
Henschke, Nicholas .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (11)
[8]   Test-based exact confidence intervals for the difference of two binomial proportions [J].
Chan, ISF ;
Zhang, ZX .
BIOMETRICS, 1999, 55 (04) :1202-1209
[9]   Long-Term Biological and Behavioural Impact of an Adolescent Sexual Health Intervention in Tanzania: Follow-up Survey of the Community-Based MEMA kwa Vijana Trial [J].
Doyle, Aoife M. ;
Ross, David A. ;
Maganja, Kaballa ;
Baisley, Kathy ;
Masesa, Clemens ;
Andreasen, Aura ;
Plummer, Mary L. ;
Obasi, Angela I. N. ;
Weiss, Helen A. ;
Kapiga, Saidi ;
Watson-Jones, Deborah ;
Changalucha, John ;
Hayes, Richard J. .
PLOS MEDICINE, 2010, 7 (06)
[10]   Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial [J].
Einstein, Mark H. ;
Takacs, Peter ;
Chatterjee, Archana ;
Sperling, Rhoda S. ;
Chakhtoura, Nahida ;
Blatter, Mark M. ;
Lalezari, Jacob ;
David, Marie-Pierre ;
Lin, Lan ;
Struyf, Frank ;
Dubin, Gary .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) :3435-3445